November 22, 2016
KynderMed Announces The Promotion of Melanie Simmons, PhD to CEO
KynderMed, Inc. is developing a new and exciting technology targeted at reducing the tragedies associated with preterm birth. The Company has announced that Melanie Simmons, PhD, has been promoted to President and CEO.
May 20, 2016
KynderMed Invited to Participate in The Healthbox Florida Studio in Partnership with GuideWell Innovation
Don Rosenkoetter, KynderMed President and CEO, announced, “We are excited and honored that KynderMed has been invited to participate in the The Healthbox Florida Studio in Partnership with GuideWell Innovation…”
April 30, 2016
St. Pete company’s sleep mask that offsets early labor wins $50,000
Gainesville Sun – A sleep mask that will help at-risk women avoid the onset of premature labor won the $50,000 Cade Museum Prize for Innovation Saturday night.
The mask’s creator is a St. Petersburg-based company called KynderMed.
View all Press Releases
KynderMed is a privately held, recently formed Women’s Health Company initially focused on reducing the human tragedy and economic burden caused by preterm labor. The magnitude of the global problem is staggering: one million infant deaths per year and an estimated $50+ billion expended in healthcare system costs. Currently there is no therapy that can effectively and safely address this unmet medical need. KynderMed’s first product will create a $2+billion market.
KynderMed will leverage new and proprietary insights into the suppression and induction of labor resulting from regulation of melatonin. These technologies are the product of research conducted at Florida State University.
KynderMed has an option for an exclusive license covering patents that will enable the development of two unique products in the short to intermediate term:
The first initiative is a simple, non-invasive medical device called Cerulean Sleep, which will enable at-risk women to avoid the onset of premature labor. Annually, more than one million infants die as a result of premature birth worldwide.
The device uses a specific blue light spectrum therapy to control the production of the hormone melatonin to suppress contractions. The technology has been successfully tested and is currently in a second proof of concept human trial. Collaborators include Brigham and Women’s Hospital (Harvard) and Rensselaer Polytechnic Institute.
Near-term activities include design completion, usability testing and two small clinical studies. Cerulean Sleep will be submitted for regulatory approval in the US and EU. It is anticipated that approval will occur in late 2016 and that Cerulean Blue will be launched in early 2017.
The second initiative is a pharmaceutical application derived from additional insights into melatonin. It offers promise as a kinder, more natural, and much less dangerous labor induction agent than the current standard (Oxytocin), which produces a high incidence of fetal distress.